Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Antibody–drug conjugates (ADCs) are becoming increasingly prominent in the oncology landscape. Eleven ADCs are marketed worldwide for haematological and solid tumour malignancies, of which six have gained regulatory approval since 2019. Most ADCs comprise a cytotoxic agent attached to a monoclonal antibody (mAb) that targets a specific tumour-associated antigen. This approach combines the targeted delivery of the mAb with the tumour-killing potential of the payload, which is generally too toxic to be systemically administered.